Literature DB >> 10736499

In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathologic outcomes.

T R Larson1, D W Rrobertson, A Corica, D G Bostwick.   

Abstract

OBJECTIVES: To determine the critical temperatures below which human prostatic tissue can be cryoablated in situ and the comparative cryoablative efficacy of single versus double-freeze cryosurgery.
METHODS: Six patients with prostate cancer previously scheduled for prostatectomy underwent unilateral or bilateral cryosurgery using a single cryosurgery probe per hemiprostate. Intraprocedural interstitial prostatic temperatures were measured by thermocouple junctions placed at various radial distances from the probe. After subsequent prostatectomy, whole-mount sections of the prostate gland were subjected to histopathologic evaluation.
RESULTS: Uniform coagulative necrosis was observed in proximity to the cryosurgery probe. The percentage of the prostate volume falling within the zone of necrosis produced by a single probe was significantly greater (P = 0.048) after a double freeze (median 13%; range 8% to 20%) than a single freeze (median 4%; range 0% to 12%). The critical temperature for cryoablation with a double freeze was -41.4 degrees C (95% confidence interval -49.9 degrees to -33.0 degrees C) compared with -61.7 degrees C (95% confidence interval -74.5 degrees to -48.9 degrees C) for a single freeze (P <0.0005).
CONCLUSIONS: Uniform coagulative necrosis of human prostatic tissue in vivo can be accomplished throughout a significantly larger zone with a double freeze than with a single freeze. A double freeze at temperatures below approximately -40 degrees C results in necrosis. These findings provide a basis for more optimal use of temperature monitoring during cryosurgery, which is essential to ensure effective treatment of the entire prostate gland with minimum risk of damage to adjacent tissues such as the rectum and external sphincter.

Entities:  

Mesh:

Year:  2000        PMID: 10736499     DOI: 10.1016/s0090-4295(99)00590-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

Review 1.  Cryotherapy.

Authors:  Katsuto Shinohara
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

Review 2.  [Cryoablation of localized prostate cancer. Current state].

Authors:  U K F Witzsch; E Becht
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

Review 3.  Percutaneous Image-Guided Cryoablation in Vascular Anomalies.

Authors:  Raja Shaikh
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

4.  Efficiency of cryotherapy in avoiding myringotomy closure in rats.

Authors:  Felician Chirteş; Veronica Trombitas; Diana Vlad; Flaviu Tabaran; Cristian Berce; Silviu Albu
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-10-17

5.  Salvage cryosurgery of the prostate after radiation failure.

Authors:  John S Lam; Arie S Belldegrun
Journal:  Rev Urol       Date:  2004

6.  Cryoinsult parameter effects on the histologically apparent volume of experimentally induced osteonecrotic lesions.

Authors:  Jessica E Goetz; Duane A Robinson; Douglas R Pedersen; Michael G Conzemius; Thomas D Brown
Journal:  J Orthop Res       Date:  2011-01-21       Impact factor: 3.494

7.  [Cryoablation of prostate cancer].

Authors:  U K F Witzsch; E Becht
Journal:  Urologe A       Date:  2015-02       Impact factor: 0.639

Review 8.  Oncologic outcomes for ablative therapy of kidney cancer.

Authors:  Sangtae Park; Jeffrey A Cadeddu; W Bruce Shingleton
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

9.  [Cryoablation of prostate cancer].

Authors:  U K F Witzsch; K Skriapas; E Becht
Journal:  Urologe A       Date:  2008-04       Impact factor: 0.639

10.  Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy.

Authors:  M Ismail; S Bokaee; Richard Morgan; J Davies; K J Harrington; H Pandha
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.